Pharmacoeconomic analysis of @entity4382 (recombinant XXXX @entity4382 ) for secondary prophylaxis of @entity882 in solid tumor @entity1 receiving chemotherapy.

@entity1 @entity8033 @entity882 @entity4382
BACKGROUND: Previous research has shown @entity4382 (recombinant @entity1 @entity4382 [ @entity8033 ]) to be effective in reducing the requirements for platelet transfusions after myelosuppressive chemotherapy in @entity1 who have previously experienced @entity882 . The economic consequences of the routine use of this platelet growth factor and the usual standard of platelet transfusions for prophylaxis of severe chemotherapy-induced @entity882 have not been compared. METHODS: The authors constructed a decision-analytic model to compare the alternatives of @entity8033 versus usual care using probability, outcome, and cost data from previously published clinical trials and their own institutional sources. They incorporated the costs of platelet transfusions and adverse events from @entity8033 into the analysis. Quality-of-life outcomes were not considered. The pharmacoeconomic analysis was based on the criterion of cost minimization from the payer's perspective. RESULTS: The expected cost of the usual care strategy for prophylaxis of severe @entity882 (transfusion when platelets < 20000 microL(-1)) was US dollars 3495 for a 3-week cycle of chemotherapy. The prophylactic @entity8033 strategy was more expensive, with an expected cost of US dollars 5328 over the same time period. Nonetheless, it was associated with fewer platelet transfusions, avoiding an average of 6.7 U compared with usual care. The savings from avoidance of platelet transfusion and adverse reactions to transfusion from the use of @entity8033 were not offset by the substantial cost of the pharmaceutical. The greater expected costs from the @entity8033 strategy were relatively insensitive to the unit price and efficacy of @entity8033 and the costs of platelet transfusions and monitoring. CONCLUSIONS: From the payer's perspective, @entity8033 cannot be considered a cost-saving clinical strategy compared with routine platelet transfusions for @entity1 with severe chemotherapy-induced @entity882 .
